Journey Medical Corp Announces New Journey with the Experts Video Featuring Mark Seraly, MD — Journey Medical Corporation

Dr. Seraly discusses severe recalcitrant acne, including nodular, inflammatory and cystic acne

 

SCOTTSDALE, Ariz.July 9, 2021PRLog — Journey Medical Corporation (Journey Medical) today released a new Journey with the Experts video featuring Mark Seraly, MD, a board-certified dermatologist with Seraly Dermatology in Peters Township, Pennsylvania. Dr. Seraly sits down with Journey Medical to discuss severe recalcitrant acne, including what it is, why it occurs and how those affected can seek treatment from their local dermatology practice.

Severe recalcitrant acne includes nodular, inflammatory and cystic acne. These types of acne are more serious than a typical pimple and affect deeper layers of the skin. To view the Journey with the Experts video featuring Dr. Seraly, please visit https://vimeo.com/559488131/8953d15ed4.

About Journey with the Experts

Journey with the Experts is an educational initiative supported by Journey Medical Corporation, the medical dermatology company. The initiative is designed to educate the general public on common medical dermatology skin disorders and explain how these conditions can be treated at local dermatology practices.

About Journey Medical Corporation

Journey Medical is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The company currently markets seven products that help treat and heal common skin conditions. The Journey Medical team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey Medical is located in Scottsdale, Arizona and is a partner company of Fortress Biotech, Inc. (NASDAQ:FBIO). For additional information about Journey Medical, visit https://journeymedicalcorp.com/.

About Mark Seraly, MD

Dr. Seraly is a board-certified dermatologist with over 23 years of clinical experience. Dr. Seraly is a graduate of Jefferson Medical College in Philadelphia, PA and completed his residency and chief residency in dermatology at the University of Pittsburgh. He is the recipient of numerous honors and awards including membership in many academic honor societies.

Dr. Seraly has authored 37 medical publications and has been invited as a guest lecturer over 200 times in 23 U.S. states and 11 cities in 7 foreign countries. He is an active member of many professional medical societies, former adjunct teaching faculty for the University of Pittsburgh Department of Dermatology residency program, and runs a private practice in Peters Township, PA. Dr. Seraly’s particular interests in dermatology include acne, rosacea, skin cancer, cosmetic dermatology, infectious skin diseases, autoimmune disorders and teledermatology. For additional information about Dr. Seraly, please visit http://www.drmarkseraly.com/staff.html.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words “we”, “us” and “our” may refer to Fortress individually, a partner company individually, or Fortress together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law.

LEAVE A REPLY

Please enter your comment!
Please enter your name here